Pretreatment with G-CSF Could Enhance the Antifibrotic Effect of BM-MSCs on Pulmonary Fibrosis

Figure 1

Pretreatment with G-CSF enhances the ability of BM-MSCs to inhibit BLM-induced pulmonary fibrosis. C57BL/6 mice were given BLM on day 0, and on Day 14, BM-MSCs were injected into the tail vein. Mice were sacrificed on day 21, and lung tissues were obtained for analysis (a–e). Lung sections were pathologically examined using H&E staining (a) and Masson trichrome staining (b) (section thickness = 3– μm; scale bar = 100 μm, ×100). (c) Collagen content was estimated by hydroxyproline assay. The mRNA expression of collagen I (d) and collagen III (e) was measured by real-time PCR. BM-MSCs(1) = 1 × 10⁵ cells, BM-MSCs(2) = 3 × 10⁵ cells, and BM-MSCs(3) = 1 × 10⁶ cells. G-CSF>BM-MSCs represented BM-MSCs pretreated with G-CSF (30 ng/mL). –5, , . Bars: mean ± SD.

(a)

(b)

(c)

(d)

(e)